Suchergebnisse - "Agarwal, Kosh"

PubPharm (13)

1

Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development : A long-term follow-up study

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2022

von Poordad, F. | Felizarta, F. | Yao, B. | +10

2

English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed

enthalten in: Alimentary pharmacology & therapeutics | 2020

von Drysdale, K. | Ntuli, Y. | Bestwick, J. | +8

3

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial

enthalten in: Journal of hepatology | 2020

von Dore, G. | Feld, J. | Thompson, A. | +18

4

Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection : An integrated phase 2/3 analysis

enthalten in: Journal of viral hepatitis | 2019

von Flamm, S. | Mutimer, D. | Asatryan, A. | +20

5

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection

enthalten in: Hepatology (Baltimore, Md.) | 2018

von Reau, N. | Kwo, P. | Rhee, S. | +19

6

Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis : A randomized trial

enthalten in: Hepatology (Baltimore, Md.) | 2018

von Foster, G. | Agarwal, K. | Cramp, M. | +18

7

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2018

von Asselah, T. | Kowdley, K. | Zadeikis, N. | +19

8

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience : A partially randomized phase 3 clinical trial

enthalten in: Hepatology (Baltimore, Md.) | 2018

von Wyles, D. | Poordad, F. | Wang, S. | +15

9

Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A) : two randomised, phase 2, open-label trials

enthalten in: The lancet. Gastroenterology & hepatology | 2017

von Gane, E. | Pianko, S. | Roberts, S. | +28

CommentIn: Lancet Gastroenterol Hepatol. 2017 Nov;2(11):771-772. - PMID 28802817

10

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis

enthalten in: Journal of hepatology | 2017

von Kwo, P. | Poordad, F. | Asatryan, A. | +19